NOT FOR DISTRIBUTION
Header cover image

Market Cap

€79.5m

Last Updated

2021/05/15 21:55 UTC

Data Sources

Company Financials +

Executive Summary

Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. More Details


Snowflake Analysis

Outstanding track record with moderate growth potential.

Share Price & News

How has Oncodesign Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALONC is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ALONC's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-1.4%

ALONC

-2.6%

FR Biotechs

-0.2%

FR Market


1 Year Return

-5.7%

ALONC

35.7%

FR Biotechs

48.4%

FR Market

Return vs Industry: ALONC underperformed the French Biotechs industry which returned 35.7% over the past year.

Return vs Market: ALONC underperformed the French Market which returned 48.4% over the past year.


Shareholder returns

ALONCIndustryMarket
7 Day-1.4%-2.6%-0.2%
30 Day-0.2%-6.0%2.6%
90 Day-15.7%-16.8%11.0%
1 Year-5.7%-5.7%35.7%35.7%52.3%48.4%
3 Year12.5%12.5%-19.8%-19.8%26.2%15.3%
5 Year-41.2%-41.2%-48.1%-48.2%78.4%55.3%

Long-Term Price Volatility Vs. Market

How volatile is Oncodesign Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oncodesign Société Anonyme undervalued compared to its fair value and its price relative to the market?

18.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALONC (€11.64) is trading below our estimate of fair value (€14.35)

Significantly Below Fair Value: ALONC is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ALONC is poor value based on its PE Ratio (48.5x) compared to the European Biotechs industry average (31.5x).

PE vs Market: ALONC is poor value based on its PE Ratio (48.5x) compared to the French market (24.5x).


Price to Earnings Growth Ratio

PEG Ratio: ALONC is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: ALONC is overvalued based on its PB Ratio (9x) compared to the FR Biotechs industry average (4.3x).


Future Growth

How is Oncodesign Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

15.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALONC's forecast earnings growth (15% per year) is above the savings rate (0.4%).

Earnings vs Market: ALONC's earnings (15% per year) are forecast to grow slower than the French market (19.3% per year).

High Growth Earnings: ALONC's earnings are forecast to grow, but not significantly.

Revenue vs Market: ALONC's revenue (11.4% per year) is forecast to grow faster than the French market (6.8% per year).

High Growth Revenue: ALONC's revenue (11.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALONC's Return on Equity is forecast to be very high in 3 years time (717.8%).


Past Performance

How has Oncodesign Société Anonyme performed over the past 5 years?

13.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALONC has high quality earnings.

Growing Profit Margin: ALONC's current net profit margins (5.5%) are higher than last year (4.6%).


Past Earnings Growth Analysis

Earnings Trend: ALONC has become profitable over the past 5 years, growing earnings by 13.8% per year.

Accelerating Growth: ALONC's earnings growth over the past year (29.6%) exceeds its 5-year average (13.8% per year).

Earnings vs Industry: ALONC earnings growth over the past year (29.6%) exceeded the Biotechs industry 21.8%.


Return on Equity

High ROE: ALONC's Return on Equity (24%) is considered high.


Financial Health

How is Oncodesign Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ALONC's short term assets (€23.7M) exceed its short term liabilities (€16.3M).

Long Term Liabilities: ALONC's short term assets (€23.7M) exceed its long term liabilities (€14.6M).


Debt to Equity History and Analysis

Debt Level: ALONC's debt to equity ratio (52%) is considered high.

Reducing Debt: ALONC's debt to equity ratio has increased from 1.2% to 52% over the past 5 years.

Debt Coverage: ALONC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: ALONC's interest payments on its debt are not well covered by EBIT (2.3x coverage).


Balance Sheet


Dividend

What is Oncodesign Société Anonyme current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALONC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALONC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALONC's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.0yrs

Average management tenure


CEO

Philippe Genne

11yrs

Tenure

€204,420

Compensation

Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010 and Chief Corporate Business Development Offic...


Leadership Team

Experienced Management: ALONC's management team is seasoned and experienced (11 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oncodesign Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncodesign Société Anonyme
  • Ticker: ALONC
  • Exchange: ENXTPA
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €79.542m
  • Shares outstanding: 6.83m
  • Website: https://www.oncodesign.com

Number of Employees


Location

  • Oncodesign Société Anonyme
  • 20 rue Jean Mazen
  • BP 27627
  • Dijon
  • Burgundy
  • 21076
  • France

Listings


Biography

Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 21:55
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.